Hypopharyngeal Cancer Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.
Conditions: Stage II-IVB Operable HNSCC Oral Cavity; Hypopharynx; Oropharynx; Larynx Interventions: Drug: Durvalumab; Drug: durvalumab + tremelimumab Sponsor: Yonsei University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 12, 2018 Category: Research Source Type: clinical trials
